For many years I coordinated the publication of articles written by participants who had attended the WFH World Congresses for the CHS newsmagazine, Hemophilia Today....
Montreal, July 5, 2024 – Canada’s two health technology assessment (HTA) agencies have made conflicting recommendations on two gene therapies for hemophilia B. Earlier in...
I had the privilege of attending the WFH 2024 World Congress in Madrid, Spain, last April, as a CHS Québec Chapter bursary recipient. From the...
The WFH 2024 World Congress was not your father’s conference! For one reason or another, I have been fortunate to attend almost every WFH World...
We had a great Canadian physiotherapy contingent in Spain for the WFH 2024 World Congress. Six physiotherapists (PTs) from across Canada (Montréal, Toronto, Hamilton, Winnipeg,...
When you go to a WFH World Congress, you go with your mind, heart and eyes open. It was my distinct privilege to be able...
In an effort to bring young volunteers into the Canadian Hemophilia Society (CHS), and in recognition that a sound education is of utmost importance, particularly...
As I began to write this article, I took a moment to reflect on my experience with bleeding disorders over the years. I have considered...
Please CLICK HERE to access the 2023 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking...
For those who follow fashion trends, you know that white dresses are trending this spring. It was easy for me to find one that suited...
In the context of the WFH 2024 World Congress, I was invited to present at the Data and Research Workshop on April 21 about how...
I have been home from the WFH 2024 World Congress in Madrid for a month now and struggling a little as to how to synthesize...
Each World Congress brings together people from all over the world. What fun it is to see friends from previous times but also to...
Montreal, May 24, 2024 – Canadian Blood Services (CBS) announced this week that the provinces and territories have agreed to expand access to emicizumab (Hemlibra)...